# A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

> **NCT01609140** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 248 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** MPSK3169A
- **DRUG:** MPSK3169A
- **DRUG:** MPSK3169A
- **DRUG:** MPSK3169A
- **DRUG:** MPSK3169A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01609140
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-07
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01609140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01609140, "A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01609140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*